Antipyretic

DRUG3 trials

Sponsors

Pediatric Brain Tumor Consortium, Ultragenyx Pharmaceutical Inc, Cinnagen

Conditions

Glycogen Storage Disease Type IIIMucopolysaccharidosis Type 1Recurrent EpendymomaRecurrent Medulloblastoma

Phase 1

Safety, Tolerability, and Pharmacokinetics of UX053 in Patients With Glycogen Storage Disease Type III (GSD III)

TerminatedNCT04990388

Ultragenyx Pharmaceutical IncGlycogen Storage Disease Type III

Start: 2021-10-18End: 2023-03-20Updated: 2024-04-16

Phase 2

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

Active, not recruitingNCT04743661

Pediatric Brain Tumor ConsortiumRecurrent Ependymoma, Recurrent Medulloblastoma

Start: 2022-04-04End: 2027-09-30Target: 62Updated: 2026-02-05

Phase 3

Efficacy and Safety of YW17 (Laronidase-CinnaGen) Compared to Aldurazyme® in MPS I Patients

CompletedNCT06406153

CinnagenMucopolysaccharidosis Type 1

Start: 2022-09-10End: 2023-11-18Updated: 2024-08-06

Related Papers

Efficacy and safety of a biosimilar laronidase versus the reference laronidase in patients with mucopolysaccharidosis type I.

2025-08-19